The estimated Net Worth of Robert A Bradway is at least $224 Million dollars as of 18 February 2021. Mr. Bradway owns over 73,500 units of AMGEN stock worth over $204,053,032 and over the last 17 years he sold AMGN stock worth over $0. In addition, he makes $19,612,800 as Chairman of the Board, President, and Chief Executive Officer at AMGEN.
Robert has made over 7 trades of the AMGEN stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 73,500 units of AMGN stock worth $4,019,715 on 18 February 2021.
The largest trade he's ever made was exercising 127,000 units of AMGEN stock on 13 April 2020 worth over $7,420,610. On average, Robert trades about 3,227 units every 20 days since 2007. As of 18 February 2021 he still owns at least 618,380 units of AMGEN stock.
You can see the complete history of Mr. Bradway stock trades at the bottom of the page.
Robert A. Bradway serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Bradway has been our President since 2010 and Chief Executive Officer since 2012. From 2010 to 2012, Mr. Bradway served as our Chief Operating Officer. Mr. Bradway joined Amgen in 2006 as Vice President, Operations Strategy and served as Executive Vice President and Chief Financial Officer from 2007 to 2010. Prior to joining Amgen, he was a Managing Director at Morgan Stanley in London where, beginning in 2001, he had responsibility for the firm’s banking department and corporate finance activities in Europe. Mr. Bradway has been a director of The Boeing Company, an aerospace company and manufacturer of commercial airplanes, defense, space and securities systems, since 2016, serving on its Audit and Finance Committees. From 2011 to 2017, Mr. Bradway was a director of Norfolk Southern Corporation, a transportation company. He has served on the board of trustees of the University of Southern California since 2014 and on the advisory board of the Leonard D. Schaeffer Center for Health Policy and Economics at that university since 2012. Mr. Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard Business School.
As the Chairman of the Board, President, and Chief Executive Officer of AMGEN, the total compensation of Robert Bradway at AMGEN is $19,612,800. There are no executives at AMGEN getting paid more.
Robert Bradway is 57, he's been the Chairman of the Board, President, and Chief Executive Officer of AMGEN since 2013. There are 17 older and 8 younger executives at AMGEN. The oldest executive at AMGEN Inc. is Fred Hassan, 74, who is the Independent Director.
Over the last 21 years, insiders at AMGEN have traded over $219,663,137 worth of AMGEN stock and bought 8,904 units worth $919,219 . The most active insiders traders include Robert Eckert, Kevin W Sharer, and Ellen Jamison Kullman. On average, AMGEN executives and independent directors trade stock every 35 days with the average trade being worth of $8,732,261. The most recent stock trade was executed by Nancy A. Grygiel on 3 May 2024, trading 2,117 units of AMGN stock currently worth $662,812.
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.
AMGEN executives and other stock owners filed with the SEC include: